up to 2 years. 7, 8 Women are dissatisfied with care and healthcare providers and report inconsistent approaches to diagnose and manage PCOS. 7, 8 Polycystic ovary syndrome is up to 70% heritable according to twin studies, is related to defined genetic abnormalities and presents a health burden that extends to the next generation, with significant adverse effects on children of affected mothers. 9, 10 It is underpinned by both intrinsic and extrinsic insulin resistance (IR) with women with PCOS generally having greater inherent IR compared to women without PCOS (intrinsic IR), exacerbated by greater IR linked to obesity (extrinsic IR). 11 Hyperandrogenism is a key feature of PCOS, although not a diagnostic prerequisite. Hyperandrogenism is driven by IR and hyperinsulinemia and is a common feature of the condition contributing to clinical features. 5 Polycystic ovary syndrome has significant multisystem reproductive, metabolic and psychosocial impacts. 6 Reproductive manifestations include infertility and adverse pregnancy outcomes; metabolic features include obesity, IR, type 2 diabetes (T2DM) and cardiovascular risk factors (CVRFs); and psychological features including depression, anxiety and poor quality of life. 5, 6 These are key health priority areas and are leading burdens of disease in women across the lifespan. Importantly, women with PCOS are at an increased risk of reproductive and metabolic risks triggered from puberty. They may also have a higher rate of longitudinal weight gain which further worsens manifestations of PCOS. This may be related to factors including dysregulation of appetite control and energy expenditure or worsened psychological health. 12 Here, we focus on the current perspectives and challenges in pregnancy implications of PCOS.
The association of PCOS with increased risk of adverse pregnancy outcomes is still contentious due to the heterogeneity in conducted studies. This heterogeneity is seen across PCOS diagnosis and clinical manifestations, prepregnancy conditions and treatments, population characteristics and lifestyle. There is also a paucity of prospective studies and a lack of clinical significance in some studies. [13] [14] [15] [16] A number of studies have been performed addressing the risk of pregnancy complications in PCOS. However, many have not addressed important considerations such as matching for prepregnancy body mass index (BMI) as a strong risk factor for both worsened PCOS manifestations and adverse pregnancy outcomes.
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| P COS AND ADVER S E PREG NAN C Y OUTCOME S: S TUD IE S AND LIMITATI ON S
Polycystic ovary syndrome and its manifestations potentially denote pregnancies in women with PCOS as high-risk pregnancies, requiring additional antenatal care. These manifestations include endocrine disorders and diabetes, obesity, multiple pregnancy and having a history of adverse pregnancy outcomes. Despite this, PCOS
is not a factor assessed in routine antenatal screening for identifying high-risk pregnancies. 17 For those already diagnosed with PCOS, preconception assessment of BMI, blood pressure and oral glucose tolerance is recommended by the Endocrine Society guidelines for the diagnosis and treatment of PCOS. 18 This recommendation is consistent with the results of several conducted meta-analyses which showed an increased risk for adverse pregnancy outcomes in women with PCOS.
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| Maternal adverse pregnancy outcomes
There is inconsistent evidence suggesting increased risk for miscarriage in women with PCOS. The most recent meta-analysis found women with PCOS to be at a 2.9-fold (95% CI: 1.6, 5.0) higher risk for miscarriage compared to women without PCOS. 16 However, results vary by study design, even among the studies which recruited women from infertility treatment clinics. Figure 1 summarizes the variations in diagnosis of PCOS and its components in studies investigating pregnancy outcomes.
| Foetal and infant complications
Maternal pregnancy complications may interact with PCOSrelated risk factors and further worsen foetal and infant outcomes.
Meta-analyses report offspring of mothers with PCOS tend to be born earlier than those to mothers without PCOS. [13] [14] [15] [16] However, it is generally not reported in these studies whether preterm birth (PTB) was spontaneous or induced. 13 It is therefore difficult to know whether the primary reason for PTB is spontaneous start of labour or medically indicated preterm delivery due to foetal or maternal pathology.
Animal studies suggest that hyperandrogenism may disturb foetal growth 33 ; however, it may alternatively increase foetal size if presenting with IR/hyperinsulinemia. 34 On the other hand, chronic hyperinsulinemia may restrict foetal growth through interfering with normal vascular function. 35 Different cut-off points used for defining hyperandrogenism and hyperinsulinemia across studies could therefore contribute to diverse results. In a study with 400 age-and BMI-matched obese women with and without PCOS, no foetus was diagnosed with intrauterine growth restriction (IUGR). 19 However, Wang et al 36 reported IUGR to be more prevalent in women with PCOS compared to controls of similar age and BMI. Meta-analyses have also reported similar risks for small for gestational age (SGA) birth among infants born to mothers with and without PCOS 13, 16 although discrepant results in individual studies are noted. 25, 26 The risk of large for gestational age (LGA) birth does not seem to change significantly by PCOS status. 27, 36 Given the underlying effect of hyperinsulinemia and obesity in the pathophysiology of the PCOS 11 and higher risk of GDM among women with PCOS, 16 a higher risk for
LGA birth may be expected among women with PCOS. The opposite results may highlight the importance of consideration of lifestyle as and insulin resistance in women with PCOS. 37 As expected following a more complicated pregnancy, infants born to mothers with PCOS are at higher risk for being admitted to neonatal intensive care unit (NICU) in meta-analyses (OR: 2.3; 95% CI: 1.4-3.8). 13, 15 The higher proportion of prematurity and its related disorders such as respiratory distress syndrome increase the risk of being admitted to NICU. 30 While a study which analysed admission to NICU by the reason for admission, revealed identical risk among women with and without PCOS, 38 Bjercke et al reported higher admission to NICU for infants born to women with PCOS. However, they proposed these results might be attributed to routine admission for infants born to mothers with GDM which was more prevalent in women with PCOS. 39 The risk of perinatal mortality has also been reported to be higher among infants born to mothers with PCOS due to increased rate of multiple pregnancies and preterm birth. 13 In addition, we note prior meta-analyses reporting an increased risk of perinatal mortality for children of women with PCOS included a study which reported outcomes in women who had more than one pregnancy during the study period 31 while the women in remaining studies had only one pregnancy. 13, 16 It is known that the risk of recurrence of pregnancy complications is high in subsequent pregnancies. 40 As such, the reported increased ORs in these meta-analyses may be affected by this heterogeneity.
| P OSS IB LE CONTRIBUTING MECHANIS MS OF P COS IN ADVER S E PREG NAN C Y OUTCOME S
| PCOS phenotypes and adverse pregnancy outcomes
There is some evidence that metabolic features of PCOS differ across the diagnostic criteria with a higher prevalence of obesity and IR and worsened metabolic features reported for women diagnosed according to the NIH in comparison with the Rotterdam criteria. 41, 42 
| Contributing effect of IR in adverse pregnancy outcomes
Insulin resistance and hyperinsulinemia occur in 50%-80% of women with PCOS which drive hyperandrogenism either directly through augmenting androgen production or indirectly through reducing sex hormone-binding globulin (SHBG) production. 6 Once women with PCOS conceive, a normal pregnancy-induced IR is superimposed on the prepregnancy IR predisposing women to an increased risk to develop GDM. 13 However, a study by Bjercke et al on singleton pregnancies among 23 IR and 29 non-IR women with PCOS and 355 controls reported no differences in GDM in the IR women with PCOS compared to both non-IR women with PCOS and controls. 39 Higher risk for GDM has been reported among normal and overweight women with PCOS in association with elevated higher baseline insulin levels compared to their age-and BMI-matched controls. 25, 26 Insulin has been shown to have both direct and indirect effect on vessels leading to vasoconstriction and HDP. 45 Insulin also promotes prothrombotic and profibrotic effects through provocation of various growth factors. 46 Hyperinsulinemia may augment the blood pressure response to sodium intake. 46 IR per se has also been found to be associated with an increased risk of developing GH and PE. 39 The presence of vascular disorder is associated with poor perinatal outcomes including an increased risk of PTB, CS, perinatal death and growth disorders in the growing baby resulting in lower LGA and higher SGA birth. 35 This emphasizes the important role of hyperinsulinemia in the development of adverse pregnancy outcomes in women with PCOS.
| Contributing effect of obesity in adverse pregnancy outcomes (BMI and gestational weight gain)
It is estimated that up to 61% of women with PCOS are overweight or obese from pooled meta-analyses data. 37 
| Contributing effect of inflammation in adverse pregnancy outcomes
In PCOS, a state of low-grade chronic inflammation may be induced -1) ). 43, 48 On the other hand, normal physiological changes in pregnancy include the aberration of maternal immune system where elevated WBC count and CRP levels have been observed. 43 A prospective study by Palomba et al 43 confirmed that compared to women without PCOS, those with PCOS have higher serum levels of inflammatory markers (WBC and CRP) prior to pregnancy with significantly higher elevations in pregnancy associated with adverse maternal and neonatal outcomes such as GDM, GH, PE, PTB, antepartum haemorrhage, SGA and LGA. 28, 43, 44 The underlying mechanism of inflammation in adverse pregnancy outcomes and particularly in PCOS is poorly understood.
| Contributing effect of infertility and multiple pregnancy in adverse pregnancy outcomes
Despite a high proportion (74%) of women with PCOS being able to conceive spontaneously in some reported studies, up to 76% of women with PCOS seek advice or treatment for infertility. 49 Furthermore, women with PCOS account for 17% of assisted reproductive technology (ART) in Poland, 50 and in a longitudinal cohort in Australian women, this was even higher at 40% of ART. and congenital malformations 5.7% (95% CI 4.7-6.9). 54 It should be noted that infertility 52, 53 and maternal pregnancy complications 13 probably share some of the underlying causes of foetal and infant complications.
First-line pharmacological treatment for anovulatory infertility in
women with PCOS is ovulation induction in the order of preference of letrozole, clomiphene citrate (with or without metformin) and gonadotropins. These medications may increase the rate of multiple pregnancy or ovarian hyperstimulation syndrome or be associated with gastrointestinal disturbances. 18, 55 Adding to the complexity, multiple pregnancy confers increased risk of adverse pregnancy outcomes such as PTB and LBW and multiple pregnancy is generally increased in women undergoing ART to achieve a pregnancy, albeit with significant geographical variation (4%-27%). 56 A study by Løvvik et al 28 on twin pregnancies in women with and without PCOS supports an increased risk of PTB and very PTB in women with PCOS, but not for LBW after adjustment for gestational age.
Furthermore, multiple pregnancy from ART has recently been reported in a systematic review of dichorionic diamniotic twin pregnancies to be associated with further increased adverse pregnancy outcomes including placenta praevia, PTB, very PTB, LBW and congenital malformation. 54 Thus, pregnancy in infertile or subfertile women with PCOS is associated with an increased risk of adverse outcomes which may be further exacerbated by factors including infertility treatment and multiple pregnancy.
| CURRENT TRE ATMENTS FOR ADVER S E PREG NAN C Y OUTCOME S AND THEIR IMPLEMENTATI ON IN WOMEN WITH P COS
| The role of lifestyle
Lifestyle management is recommended as a key initial treatment strategy for women with PCOS and first-line therapy according to evidencebased guidelines. 55 This is defined as multidisciplinary dietary, exercise and behavioural management with the aim of preventing weight gain or achieving and maintaining a modest weight loss and of optimizing health behaviours. The general consensus is that lifestyle management aimed at achieving modest weight loss (5%-10%) prior to pregnancy can improve reproductive outcomes in women with PCOS, although a Cochrane review has noted relatively limited research in this area. 57 More recent data have supported this in a post hoc analysis of two randomized controlled studies reporting increased pregnancy and live birth in women with PCOS, obesity and infertility who undertook a lifestyle programme followed by clomiphene compared with women who commenced clomiphene treatment immediately. 58 Lifestyle recommendations are also present in international guidelines relating to pregnancy in the general population.
These include guidelines on optimizing diet and physical activity (PA)
for achieving BMI-specific GWG within the Institute of Medicine (IOM) recommendations 59 and for specific conditions such as GDM. 24 The IOM recommends women aim to conceive at a healthy weight and that women should aim for a GWG of 11.5-16 kg for women with a healthy BMI, 7-11.5 kg for overweight women and 5-9 kg for obese women. 
| The role of medications
| Metformin
Metformin is a well-established, low priced and nontoxic antidiabetic drug, which crosses the placenta. 62 While it has been used in GDM during pregnancy for decades, there is more limited research assessing its use specifically in PCOS with relatively few randomized controlled trials (RCTs). A systematic review of 17 RCTs reported no evidence of a protective effect of preconception metformin on miscarriage compared to placebo. 22 While nonrandomized studies reported decreased rates of GDM and PE in women with PCOS treated with metformin during pregnancy, 63 a meta-analysis of RCTs on GDM 64 and an RCT on PE 65 failed to show a protective effect of metformin. Conversely, both nonrandomized studies 63 and pooled data from two randomized studies 66 show a preventive effect of metformin on PTB. It appears there is still insufficient research to confirm this relationship, and data from a large ongoing RCT are awaited.
Metformin has also been shown to result in lower GWG and larger head circumference in the offspring born to mothers with PCOS compared to placebo in an RCT. 65 There is no evidence of teratogenicity of metformin intake during pregnancy. 63 However, data on short-and long-term health effects of metformin on the offspring in PCOS are scarce. Overall, the role of metformin during pregnancy in PCOS without diabetes remains unclear. Routine metformin use is therefore not recommended.
| Myo-inositol
Myo-inositol is a cyclitol naturally present in animal and plant cells.
Myo-inositol has insulin-mimetic effects, and altered metabolism of inositol is involved in IR and diabetes. 67 A recent meta-analysis of ten RCTs found no data on the effect of inositol on miscarriage in women with PCOS. 68 However, an RCT on women with a parent with T2DM reported that myo-inositol treatment during pregnancy reduced the incidence of GDM in women with an increased risk for developing GDM, 69 a finding confirmed by a retrospective study in women with PCOS. 70 The effect of myo-inositol on pregnancy outcomes in women with PCOS is still unclear.
| The importance of family planning
A significant proportion of pregnancies are unplanned worldwide which limits opportunities to provide preconception care measures to improve health and pregnancy outcomes. These include, among others, ensuring immunizations are current, preconception folate and support for weight management and smoking cessation, where appropriate. This is particularly important in women with PCOS who are more likely to experience subfertility and infertility and more likely to have increased BMI. It is vital that women with PCOS who may experience oligo/anovulation and commence hormonal regulation of cycles are aware that their menstrual cycles may be similar when ceasing the treatment and they may experience a delay in achieving pregnancy. They should also be aware that the chance of a conception decreases with age with a significant decline in fertility noted from the age of 35. 6, 55 It is therefore important that a woman is able to have an informed reproductive life plan. This needs to be discussed in a patient-centred manner.
| CON CLUS IONS
Although meta-analyses have previously reported increased risk of adverse pregnancy outcomes in women with PCOS, it is difficult to decipher the contribution of PCOS status per se to these pregnancy outcomes due to the methodological diversity of studies and the het- 
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